1. Landis S, Murray T, Bolden S, Wingo P: Cancer statistics. CA Cancer J Clin 49:8-31, 1999.

2. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials [see comments]. J Clin Oncol 10:334-342, 1992.

3. Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous Stem cell transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome [see comments]. N Engl J Med 335:91-97, 1996.

4. Desikan R, Barlogie B, Sawyer J, et al.: Results of highdose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010, 2000.

5. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 16:3832-3842, 1998.

6. Anderson K: Who benefits from high-dose therapy for mulitple myeloma? J Clin Oncol 13:1291-1296, 1995.

7. Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999.

8. Schlossman RL, Anderson KC: Stem cell transplantation in multiple myeloma. Curr Opin Oncol 11:102-108, 1999.

9. Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003.

10. Segeren CM, Sonneveld P, van der Holt B, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101:2144-2151, 2003.

11. Attal M, Harousseau JL, Facon T, et al.: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003.

12. Rill DR, Santana VM, Roberts WM, et al.: Direct demonstration that autologous stem cell transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380-383, 1994.

tion of the existence of the GvM myeloma effect has renewed interest in allogeneic transplantation in patients with myeloma, now using a nonmyeloablative approach in hopes of reducing toxicity related to the transplant procedure. DLI remains an effective method for inducing a GvM effect, and the role of DLI after nonmyeloablative transplant is being defined. Efforts to identify the targets, mechanism of action of the GvM effect, as well as methods to enhance the GvM effect are underway. Identification of targets and an understanding of the mechanism of action may lead to more specific allogeneic immune therapies in the future.

13. Gahrton G, Tura S, Ljungman P, et al.: Allogeneic Stem cell transplantation in multiple myeloma. N Engl J Med 325:1267-1273, 1991.

14. Gahrton G, Tura S, Ljungman P, et al.: Prognostic factors in allogeneic Stem cell transplantation for multiple myeloma [see comments]. J Clin Oncol 13:1312-1322,

0 0

Post a comment